Testing a new cream for palmoplantar pustulosis
Treatments studied
Part of Skin clinical trials.
This trial tests a cream called delgocitinib for people with mild to severe palmoplantar pustulosis (PPP), a skin condition with pustules on the palms and soles. The cream is applied daily for 16 weeks to see if it improves symptoms and is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with palmoplantar pustulosis (PPP) for more than 6 months.
- You have at least 5 fresh pustules on your palms or soles at the start of the trial.
- You have tried topical steroids before and they did not work well, or your doctor says they are not right for you.
- You are not pregnant or breastfeeding and will use effective birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called bimekizumab for people with palmoplantar pustulosis (PPP), a skin condition causing painful pustules on the palms and soles. The goal is to see if the drug can clear these pustules and improve symptoms.
This trial tests whether combining two medications, tofacitinib and imatinib, can help treat moderate-to-severe palmoplantar pustulosis (PPP). PPP causes painful pustules on the palms and soles. This study is for people whose PPP is active and has not improved significantly on its own.
This study tests a new drug (Xeligekimab) for people with moderate to severe palmoplantar pustulosis — a condition causing painful blisters on the hands and feet. It may be an option if other treatments haven't worked well.
This trial tests a new oral medication, ivarmacitinib, for adults with palmoplantar pustulosis (PPP) who haven't gotten better with standard treatments. It aims to see if the drug is safe and effective for reducing the painful pustules on the palms and soles.
This trial tests a cream called delgocitinib for adults with lichen sclerosus in the genital area. It aims to see if the cream can safely and effectively reduce symptoms over 52 weeks.
This study tests a new pill called zasocitinib for adults with psoriasis on the palms and soles. It aims to see if the pill can reduce the severity of these stubborn patches without serious side effects.
Hear when a new Palmoplantar Pustulosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.